Friday December 14, 2018

Over 10,000 people screened for Diabetes and its health implications in Mumbai

Over 10,000 people were screened for diabetes and its health implications

0
//
Diabetes (Representational image). Wikimedia
Republish
Reprint

Mumbai, Jan 28, 2017: Over 10,000 people were screened for diabetes and its health implications during a diabetes mela held here on Saturday.

The medical camp inaugurated by Maharashtra Education Minister Vinod Tawde, was organised to check the health status of the people here living with the risk of diabetes.

According to the organisers — Gadge Diabetes Center — the mela highlighted the effects and causes of diabetes with the help of skits, music and dance. “The mela helped spread a positive message,” the centre said in a statement.

Look for latest news from India in NewsGram

India is considered as the Diabetes Capital of the world and as per the 2015 reports from International Diabetes Federation, 69.1 million people in India are diabetic.

“Diabetes is increasing exponentially in our country. The only way to curb is to create maximum awareness. By ensuring maximum people are a part of the awareness campaigns we can take a step forward in reducing diabetes,” Pradeep Gadge, Chief Diabetologist, Gadge Diabetes Centre, said.

A recent study at the University of California, San Francisco revealed that alcohol addiction can increase the risk factors of diabetes and high blood pressure. (IANS)

Click here for reuse options!
Copyright 2017 NewsGram

Next Story

New Drug Offers Treatment For Diabetes-Related Blindness

The researchers now plan to conduct a full-scale clinical trial, Gamble said

0
new policy will see the launch of 12 programmes relevant to private schools across the emirate
New drug offers hope for diabetes-related blindness.

In a major breakthrough, Australian scientists have developed a new drug that offers treatment for people suffering from diabetic retinopathy — the main cause of blindness from diabetes.

The debilitating disease occurs when tiny blood vessels in the retina, responsible for detecting light, leak fluid or haemorrhage.

While treatment options include laser surgery or eye injections of anti-vascular endothelial growth factor (VEGF), they are not always effective or can result in side effects, highlighting the need for alternative therapeutic approaches.

The team from the Centenary Institute in Sydney developed a novel drug CD5-2, which in mouse models was found to mend the damaged blood retinal barrier and reduce vascular leakage.

“We believe CD5-2 could potentially be used as a stand-alone therapy to treat those patients who fail to respond to the anti-VEGF treatment. It may also work in conjunction with existing anti-VEGF treatments to extend the effectiveness of the treatment,” said lead author Ka Ka Ting from the Institute.

“With limited treatment options currently available, it is critical we develop alternative strategies for the treatment of this outcome of diabetes,” Ting added.

Diabetes
Representational image. Pixabay

The key process involved in diabetic retinopathy pathology is the breakdown of the blood-retinal barrier (BRB), which is normally impermeable. Its integrity relies on how well capillary endothelial cells are bound together by tight junctions. If the junctions are loose or damaged, the blood vessels can leak.

In the study, reported in the journal Diabetologia, CD5-2 was found to have therapeutic potential for individuals with vascular-leak-associated retinal diseases based on its ease of delivery and its ability to reverse vascular dysfunction as well as inflammatory aspects in animal models of retinopathy.

Previous studies have shown that CD5-2 can have positive effects on the growth of blood vessels.

Also Read- Facebook Invests $1 mn To Boost Computer Science Education

“This drug has shown great promise for the treatment of several major health problems, in the eye and in the brain,” said Professor Jenny Gamble, head of Centenary’s Vascular Biology Programme.

The researchers now plan to conduct a full-scale clinical trial, Gamble said. (IANS)